Zhejiang Xinguang Pharmaceutical マネジメント

マネジメント基準チェック /44

Zhejiang Xinguang Pharmaceuticalの CEO はYue Jun Wangで、 Aug2012年に任命され、の在任期間は 12.25年です。は、会社の株式の38.25%を直接所有しており、その価値はCN¥ 850.68M 。経営陣と取締役会の平均在任期間はそれぞれ12.3年と6.3年です。

主要情報

Yue Jun Wang

最高経営責任者

CN¥204.6k

報酬総額

CEO給与比率	n/a
CEO在任期間	12.3yrs
CEOの所有権	38.3%
経営陣の平均在職期間	12.3yrs
取締役会の平均在任期間	6.3yrs

経営陣の近況

Recent updates

Earnings Not Telling The Story For Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519) After Shares Rise 38%

Oct 18

Zhejiang Xinguang Pharmaceutical (SZSE:300519) Has Announced That Its Dividend Will Be Reduced To CN¥0.40

May 26

Calculating The Intrinsic Value Of Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519)

Apr 16

Zhejiang Xinguang Pharmaceutical Co., Ltd.'s (SZSE:300519) Low P/E No Reason For Excitement

Feb 26

CEO（最高経営責任者

Yue Jun Wang (70 yo)

12.3yrs

在職期間

CN¥204,600

報酬

Mr. Yue Jun Wang has been Chairman of the Board and General Manager at Zhejiang Xinguang Pharmaceutical Co., Ltd. since August 25, 2012 and serves as its Director. Mr. Wang was Deputy director of pharmacis...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Yue Jun Wang	Chairman & GM	12.3yrs	CN¥204.60k	38.25% CN¥ 850.7m
Bin Bin Xing	CFO & Director	9.9yrs	CN¥163.40k	データなし
Fu Yin Qiu	Deputy GM & Director	12.3yrs	CN¥162.00k	データなし
Yuan Yang Jiang	Deputy GM	12.3yrs	CN¥165.10k	データなし

12.3yrs

平均在職期間

59yo

平均年齢

経験豊富な経営陣: 300519の経営陣は経験豊富で経験豊富です（平均在職期間は12.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Yue Jun Wang	Chairman & GM	12.3yrs	CN¥204.60k	38.25% CN¥ 850.7m
Bin Bin Xing	CFO & Director	6.3yrs	CN¥163.40k	データなし
Fu Yin Qiu	Deputy GM & Director	12.3yrs	CN¥162.00k	データなし
Yuan Yang Jiang	Deputy GM	12.3yrs	CN¥165.10k	データなし
Zhen Wang	Non-Employee Supervisor	less than a year	CN¥117.00k	データなし
Zhu Ping Sun	Chairman of the Supervisory Board	6.3yrs	データなし	データなし
Fei Jun Qiu	Supervisor	6.3yrs	データなし	データなし
Xiaolin Xing	Non Independent Director	6.3yrs	CN¥83.60k	データなし
Haijing Cai	Independent Director	less than a year	データなし	データなし
Weiguang Shan	Independent Director	less than a year	データなし	データなし
Yuyang Ma	Non-Independent Director	less than a year	データなし	データなし
Guiyuan Lv	Independent Director	less than a year	データなし	データなし

6.3yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: 300519の取締役会は経験豊富であると考えられます ( 6.3年の平均在任期間)。

Zhejiang Xinguang Pharmaceutical マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

High number of new directors

Zhejiang Xinguang Pharmaceutical Co., Ltd. Announces Board Appointments; Appoints Zhao Kaiyu as Non-Employee Supervisor

Less than half of directors are independent

Less than half of directors are independent

Recent updates

High number of new directors

Third quarter 2024 earnings released: EPS: CN¥0.08 (vs CN¥0.13 in 3Q 2023)

Earnings Not Telling The Story For Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519) After Shares Rise 38%

New major risk - Share price stability

Investor sentiment improves as stock rises 34%

Second quarter 2024 earnings released: EPS: CN¥0.017 (vs CN¥0.05 in 2Q 2023)

Zhejiang Xinguang Pharmaceutical Co., Ltd. Announces Board Appointments; Appoints Zhao Kaiyu as Non-Employee Supervisor

New minor risk - Share price stability

Investor sentiment improves as stock rises 26%

Zhejiang Xinguang Pharmaceutical (SZSE:300519) Has Announced That Its Dividend Will Be Reduced To CN¥0.40

Dividend reduced to CN¥0.40

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.68 in FY 2022)

Now 27% overvalued

Calculating The Intrinsic Value Of Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519)

Investor sentiment deteriorates as stock falls 15%

Zhejiang Xinguang Pharmaceutical Co., Ltd.'s (SZSE:300519) Low P/E No Reason For Excitement

Investor sentiment improves as stock rises 16%

Now 22% overvalued

Investor sentiment deteriorates as stock falls 20%

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.18 in 3Q 2022)

New major risk - Dividend sustainability

Zhejiang Xinguang Pharmaceutical Co., Ltd. Approves the Cash Dividend for 2022, Payment on 30 May 2023

Zhejiang Xinguang Pharmaceutical Co., Ltd. Approves the Cash Dividend

First quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.19 in 1Q 2022)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.19 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.12 in 2Q 2021)

Zhejiang Xinguang Pharmaceutical Co., Ltd. Approves Profit Distribution for 2021

Less than half of directors are independent

Zhejiang Xinguang Pharmaceutical Co., Ltd. Proposes Final Dividend for 2021

Full year 2021 earnings released: EPS: CN¥0.71 (vs CN¥0.62 in FY 2020)

Investor sentiment deteriorated over the past week

Now 23% undervalued after recent price drop

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Now 21% undervalued

Investor sentiment improved over the past week

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.18 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.12 in 2Q 2020)

Investor sentiment improved over the past week

Zhejiang Xinguang Pharmaceutical Co., Ltd. Approves Final Cash Dividend on A Shares for the Year 2020, Payable on May 28, 2021

Investor sentiment improved over the past week

Zhejiang Xinguang Pharmaceutical Co., Ltd. Proposes the Final Cash Dividend for 2020

Full year 2020 earnings released: EPS CN¥0.62 (vs CN¥0.59 in FY 2019)

New 90-day low: CN¥13.57

New 90-day low: CN¥16.09

Investor sentiment deteriorated over the past week

New 90-day low: CN¥17.00

Third quarter earnings released

Market bids up stock over the past week

New 90-day high: CN¥23.30

New 90-day high - CN¥20.29

Earnings released

Zhejiang Xinguang Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /44